

***MYCN* silencing induces differentiation and apoptosis in human neuroblastoma cells**

Jung-Hee Kang ^a, Piotr G. Rychahou ^a, Titilope A. Ishola ^a, Jingbo Qiao ^a,
B. Mark Evers ^{a,b}, Dai H. Chung ^{a,b,*}

^a Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA

^b Sealy Center for Cancer Cell Biology, The University of Texas Medical Branch, Galveston, TX 77555, USA

Received 4 October 2006

Available online 12 October 2006

Abstract

MYCN amplification strongly correlates with unfavorable outcomes in patients with neuroblastoma. The aim of this study was to investigate the role of *MYCN* in neuroblastoma cell differentiation and apoptosis. We used the technique of RNA interference to inhibit *MYCN* gene expression in neuroblastoma cells with variable expression of *MYCN*. Our results showed that inhibition of *MYCN* gene expression in *MYCN* amplified cells induced apoptosis and suppressed cell growth; neuronal differentiation also occurred after *MYCN* gene silencing. Moreover, N-myc downregulation was associated with decreased Bcl-xL protein levels and caspase-3 activation. These data show that small interfering RNA directed to *MYCN*, which plays a crucial role in neuroblastoma cell survival, may provide a potential novel therapeutic option for aggressive neuroblastomas.

© 2006 Elsevier Inc. All rights reserved.

Keywords: *MYCN*/N-myc; RNAi/siRNA; Neuroblastoma; Differentiation; Apoptosis

Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 15% of cancer-related deaths [1]. Despite recent advances in treatment options, aggressive neuroblastomas remain refractory to current therapy; the overall 5-year survival rate for patients with advanced-stage neuroblastoma is dismal at 30–40%. *MYCN* protooncogene amplification, occurring in up to 25% of neuroblastomas, has been considered the most important prognostic factor, strongly correlating to advanced-stage disease and treatment failure. Targeted overexpression of *MYCN* in transgenic mice results in the spontaneous development of neuroblastomas [2].

Identification of selective inhibitors of N-myc would be important for the development of therapeutic agents for neuroblastomas with *MYCN* amplification. Previously, antisense inhibition of *MYCN* expression in vitro was

shown to decrease neuroblastoma proliferation and promote neuronal differentiation [3]. Inhibition has been accomplished either by antisense oligonucleotides targeted to N-myc mRNA or by expression vectors designed to generate N-myc antisense RNA [4]. However, a major clinical limitation of conventional antisense oligonucleotides is that they are rapidly degraded by nucleases. Recently, RNA interference (RNAi) to knock down gene expression has gained significant interest as a potential novel agent for cancer therapy. RNAi silences gene expression through short interfering 21–23-mer double-strand RNA segments that guide mRNA degradation in a sequence-specific fashion [5].

Here, we report targeted inhibition of *MYCN* transcription by RNAi and demonstrate its differential effect in *MYCN* amplified and non-amplified human neuroblastoma cell lines. Selective and specific inhibitory effects on *MYCN* transcription induced growth arrest and apoptosis, which correlated with the level of N-myc expression. Thus, RNAi-mediated post-transcriptional silencing offers a

* Corresponding author. Fax: +1 409 772 4253.

E-mail address: dhchung@utmb.edu (D.H. Chung).

potentially powerful tool to silence *MYCN* gene expression and may provide novel adjuvant treatment for selected neuroblastomas.

Materials and methods

Materials. N-myc antibody was purchased from EMD Biosciences (San Diego, CA). Anti-Bcl-xL, caspase-3, and cleaved caspase-3 antibodies and cell lysis buffer were obtained from Cell Signaling Technology (Beverly, MA). Anti-neuron specific enolase (NSE) was obtained from Abcam (Cambridge, MA). Anti β -actin monoclonal antibody and fetal bovine serum (FBS) were from Sigma (St. Louis, MO). NuPAGE Novex 4–12% Bis-Tris Gel and Lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA). Horseradish Peroxidase (HRP)-conjugated secondary antibodies against mouse and rabbit IgG were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Cell Death Detection ELISA^{Plus} was purchased from Roche Applied Science (Indianapolis, IN).

Cell culture. Human neuroblastoma cell lines, SK-N-SH, SH-SY5Y, IMR-32, and BE(2)-C, were purchased from American Type Culture Collection (Manassas, VA). JF, a primary neuroblastoma cell line, was a gift from Dr. Jason M. Shohet (Baylor College of Medicine, Houston, TX) and LAN-1 was a gift from Dr. Robert C. Seeger (University of Southern California, Los Angeles, CA). Cells were maintained in RPMI 1640 medium with L-glutamine (Cellgro Mediatech, Inc. Herndon, VA) supplemented with 10% FBS. The cells were maintained at 37 °C in a humidified atmosphere of 95% air and 5% CO₂.

Small interfering (si) RNA transfection. siRNA against *MYCN* (siMYCN) and non-targeting control (siNTC) was purchased from Dharmacon, Inc (Lafayette, CO). Cell culture transient transfection was carried out with Lipofectamine 2000 transfection reagent according to the manufacturer's protocol. Cells were seeded on 6-well plates for RNA or protein preparation and 96-well plates for DNA fragmentation or cell growth assays. After 24 h incubation, media were replaced to serum-free RPMI 1640 containing siRNA (150 nM) and transfection reagent. Cells were harvested for assays daily for three consecutive days after transfection with the siRNA duplexes. The experiments were repeated on at least three separate occasions.

RNA isolation and real-time RT-PCR. The total cellular RNA extraction was carried out using RNeasy kit (Ambion, Inc., Austin, TX) according to manufacturer's instructions. Applied Biosystems assays-on-demand 20× assay mix of primers and TaqMan MGB probes (FAMTM dye-labeled) for target gene, human *MYCN* (NCBI Accession No. [NM 005378](#) [GenBank]), and pre-developed 18S rRNA (VICTM-dye labeled probe) TaqMan[®] assay reagent (P/N 4319413E) for endogenous control were utilized. The probe sequences of human *MYCN* were ACCCTGAGCGATTGATGATGAAG. Singleplex one-step reverse transcription (RT)-PCR was performed with 80 ng RNA for both target gene and endogenous control. The reagent used was TaqMan one-step RT-PCR master mix reagent kit (P/N 4309169). The cycling parameters for one-step RT-PCR were as follows: reverse transcription 48 °C for 30 min, AmpliTaq activation 95 °C for 10 min, denaturation 95 °C for 15 s, and annealing/extension 60 °C for 1 min (repeat 40×) on ABI7000. Duplicate C_T values were analyzed in Microsoft Excel using the comparative C_T ($\Delta\Delta C_T$) method as described by the manufacturer (Applied Biosystems). The amount of target ($2^{-\Delta\Delta C_T}$) was obtained by normalized to endogenous reference (18 s) and relative to a calibrator (one of the experimental samples).

Western blot analysis. Whole-cell lysates were prepared using cell lysis buffer with 1 mM PMSF and incubated on ice for 30–60 min. Total protein (50 μ g/lane) was resolved on NuPAGE Novex 4–12% Bis-Tris gels and electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA). Nonspecific binding sites were blocked with 5% milk in TBST (120 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20) for 1 h at room temperature or overnight at 4 °C. Target proteins were detected by using rabbit or mouse anti-human antibodies (1:500–1000 dilution) for 3 h at room temperature or overnight at 4 °C. The membranes were washed three times and incubated with secondary antibodies (1:5000 dilution) conjugated with HRP.

Immune complexes were visualized using the enhanced chemiluminescence (ECL) system (Amersham Biosciences, Arlington, IL). Equal loading and transfer were confirmed by blotting the same membrane with β -actin antibody (1:5000 dilution). Data are representative of three independent experiments with nearly identical results.

DNA fragmentation assay. Apoptosis was measured using a DNA fragmentation assay as previously described [6]. Briefly, cells (100 μ l; 5–10 $\times 10^3$ cells/well) were plated in triplicate 24 h before transfection. Cells were then treated with control siRNA or *MYCN* smartpool siRNA for 48 and 72 h. Cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) were detected using a Cell Death Detection ELISA^{Plus} kit according to manufacturer's recommended protocol. The experiments were repeated on at least three separate occasions.

Cell proliferation assay. Cells were seeded in 96-well plates at a density of 5–10 $\times 10^3$ cells/well in RPMI 1640 culture medium with 10% FBS and grown for up to 3 days after transfection. Cell numbers were assessed by using Cell-Counting Kit-8 (Dojindo Molecular Technologies, Inc., Gaitersburg, MD) daily. Each assay point was performed in triplicate, and the experiment was repeated three times for each cell line. The values, corresponding to the number of viable cells, were read at OD450 with EL808 Ultra Microplate Reader (Bio Tek Instrument, Inc., Winooski, VT).

Morphological analysis. *MYCN* amplified BE(2)-C, LAN-1, and IMR-32 cells were cultured for up to 48 h in 6-well plates in the presence of siNTC or siMYCN (150 nM). Microscopic assessment for cellular differentiation was performed with an ECLIPSE-100 (Nikon instruments Inc., Lewisville, TX). The experiment was repeated twice.

Statistical analysis. Scoring index, relative DNA fragmentation, cell growth, and DNA synthesis were expressed as means \pm SEM; statistical analyses were performed using one-way analysis of variance for comparisons between the treatment groups. A *P* value of <0.05 was considered significant.

Results

MYCN transcript and N-myc protein depletion by *MYCN* siRNA

To examine the effect of *MYCN* siRNA on *MYCN* expression, we used *MYCN* amplified (LAN-1, IMR-32, and JF) and *MYCN* non-amplified (SK-N-SH) human neuroblastoma cell lines. Immunoblotting demonstrated N-myc protein expression was significantly decreased in LAN-1, IMR-32, and JF cell lines. In contrast, no change was observed in *MYCN* non-amplified SK-N-SH cells (Fig. 1A). To examine whether the reduction of N-myc protein was linked to a modification in gene expression, cells were treated with siNTC or with siMYCN over a time course (8, 12, and 24 h), and total cellular mRNA was extracted for analysis of *MYCN* transcripts by real-time RT-PCR. As shown in Fig. 1B, siMYCN resulted in significant *MYCN* mRNA reduction (40–60%) in LAN-1, IMR-32, and JF cell lines after 8 h treatment indicating that *MYCN* siRNA downregulates *MYCN* gene transcription. Comparable results were observed at 12 and 24 h post-treatment (data not shown). However, there was minimal to no *MYCN* mRNA expression noted in SK-N-SH cells.

MYCN silencing inhibits cell growth and induces apoptosis in *MYCN* amplified BE(2)-C cells

We then performed similar experiments with siMYCN treatment over a time course on BE(2)-C cells, typically




Fig. 1. Knockdown of N-myc expression using small interfering RNA in *MYCN* amplified and non-amplified neuroblastoma cell lines. (A) Western blot analysis of N-myc protein expression in *MYCN* amplified cell lines; LAN-1, IMR-32, JF, and *MYCN* non-amplified SK-N-SH cells at 24 h post-transfection with siMYCN. β-actin was used to check for equal protein loading of cell lysates. (B) Real-time RT-PCR analysis of *MYCN* mRNA expression in LAN-1, IMR-32, JF, and SK-N-SH at 6 h post-transfection. Data represent mean ± SEM; **P* < 0.05.

the tumorigenic and aggressive *MYCN* amplified human neuroblastoma cell line [7]. Significant depletion of N-myc protein level was apparent after 8 h of treatment and continued over 72 h (Fig. 2A). This led to decreases in cell growth after 48 and 72 h (16 and 30%, respectively). Consistent with the cell viability results, cell proliferation as measured by BrdU nuclear incorporation was also decreased with siMYCN treatment (data not shown). Moreover, a remarkable increase in apoptosis was detected after siMYCN treatment for 48 and 72 h (up to 2.5-fold) as measured by levels of DNA fragmentation, a hallmark of apoptosis [8] (Fig. 2C).

siMYCN-mediated reduction of Bcl-xL and caspase-3 activation in BE(2)-C cells

Despite the important role of *MYCN* in cellular processes in human neuroblastoma cells, apoptosis target protein levels induced by *MYCN* downregulation have not yet been clearly described [3,9]. Anti-apoptotic Bcl-xL blocks the release of cytochrome *c* and aborts the apoptotic response [10]. Caspase-3 is one of the key executors of apoptosis resulting in DNA fragmentation and cell death [11]. Here, we found that N-myc knockdown by siRNA against *MYCN* decreased anti-apoptotic Bcl-xL and induced cleavage of caspase-3 protein in *MYCN* amplified BE(2)-C cells (Fig. 2D).

MYCN siRNA induces apoptosis in *MYCN* amplified neuroblastoma cells

We next examined whether *MYCN* inhibition by siMYCN causes comparable apoptotic effects in other neuroblastoma cell lines with differential *MYCN* overexpression. LAN-1, IMR-32, JF, SH-5YSY, and SK-N-SH cells were plated and treated with siNTC or siMYCN over a time course (24–72 h). As shown in Fig. 3A, significant increases in apoptosis (30–72%) were observed at 48 h (IMR-32) or at 72 h (LAN-1 and JF) post-transfection in siMYCN treated groups when compared to siNTC groups as measured by DNA fragmentation. In contrast, there was no significant difference in apoptosis between siNTC treated cells and siMYCN treated cells in *MYCN* non-amplified SK-N-SH cells (Fig. 3A); this was further confirmed by Western blot analysis of SK-N-SH and SH-5YSY, another *MYCN* non-amplified cell line, for caspase-3 cleavage products (Fig. 3B).

MYCN silencing induces differentiation in *MYCN* amplified neuroblastoma cells

We have found that *MYCN* siRNA treatment results in induction of apoptosis in *MYCN* amplified neuroblastoma cells. Based on these findings, we next determined whether *MYCN* inhibition was also associated with cell differentiation. To assess the effects of siMYCN on differentiation of *MYCN* amplified neuroblastoma cells (BE(2)-C, LAN-1, and IMR-32), morphological changes were evaluated by microscopic analysis performed after 48 h in the presence of siNTC or siMYCN. *MYCN* siRNA treated cells demonstrated an increase in neurite-like projections when compared to the control cells (Fig. 4A). We then selected IMR-32 cells, which showed the most significant cellular differentiation after siMYCN treatment, to determine expression changes of neuron-specific enolase (NSE), a neuronal marker of cellular differentiation. Consistent with the morphological analysis, immunoblotting demonstrated increased protein expression of NSE in siMYCN treated cells at 8 and 12 h post-transfection (Fig. 4B).

Discussion

In this study, we show that specific, selective inhibition of *MYCN* expression by siRNA leads to cell growth inhibition in *MYCN* amplified neuroblastoma cells; cell growth inhibition was strongly associated with increased apoptosis. In contrast, no significant effect was observed in *MYCN* non-amplified neuroblastoma cells. Moreover, *MYCN* inhibition induced neuroblastoma cell differentiation. These findings underscore the significance of *MYCN* amplification and suggest a potential of developing siRNA-based treatment strategies for targeted inhibition of *MYCN* transcription.

MYCN was the first amplified oncogene that was found to be of clinical significance due to its association with




Fig. 2. siRNA-mediated inhibition of N-myc expression and expression in aggressive neuroblastoma cell line BE(2)-C. (A) N-myc protein in BE(2)-C cells transfected with siRNA against *MYCN* or NTC at 8, 12, 24, 48, and 72 h. β-Actin was used to check for equal protein loading of cell lysates. (B) WST-8 assay was used to compare the growth of siMYCN and siNTC transfected BE(2)-C cells. (C) DNA fragmentation was measured at 48, 72 h post-transfection with either siMYCN or siNTC. Data represent mean ± SEM; * $P < 0.05$. (D) BE(2)-C cells were transfected with siRNA against *MYCN* and protein levels for N-myc, Bcl-xL, and cleaved caspase-3 were detected at 48 h post-transfection. β-actin was used to check for equal protein loading.




Fig. 3. *MYCN* downregulation by RNAi induces apoptosis in *MYCN* amplified neuroblastoma cells. (A) Cells were transfected with siMYCN or siNTC and DNA fragmentation was analyzed at 48, 72 h post-transfection. Data represent mean ± SEM; * $P < 0.05$. (B) SK-N-SH and SH-SY5Y cells were transfected with siMYCN and siNTC. After 72 h, the cells were analyzed by Western blot for caspase-3 and cleaved caspase-3. β-actin was used to check for equal protein loading.

aggressive neuroblastoma phenotypes [12,13]. *MYCN* has been proven to be a critical gene for stimulation of neuroblastoma growth; therefore, considerable efforts have been directed to the design of novel molecular therapy targeted at *MYCN*. These efforts have largely met with limited success due to lack of specificity.

RNAi represents an innovative molecular tool for silencing genes at the post-transcriptional level [14]. Synthetic siRNA, introduced into post-mitotic primary neuronal cultures, can effectively reduce the expression of both endogenous and transfected genes [15]. siRNA-directed gene silencing activity has also been demonstrated in human cancer cells [16,17]. RNAi has been touted as potential targeted cancer therapy because of its impressive

specificity and efficacy. In comparison to antisense approaches, siRNAs are approximately 1000-fold more active [18]. Recent reports have demonstrated effective in vivo delivery of siRNA [19,20]. We found in this study that siMYCN can be delivered efficiently into neuroblastoma cells to produce significant knockdown of mRNA and its protein products.

Transfecting neuroblastoma cells with siMYCN produced specific attenuation of *MYCN* gene expression by 8 h which was followed by a decrease in N-myc protein product for up to 72 h. Synthetic 21 bp *MYCN* siRNAs were designed to prevent activation of the interferon (IFN) system (one of the body's defenses against viral infection) [21] as well as other off-target effects. It has been




Fig. 4. *MYCN* downregulation by RNAi induces differentiation in *MYCN* amplified neuroblastoma cells. (A) BE(2)-C, LAN-1, and IMR-32 cells were transfected with si*MYCN* or siNTC. Cell morphology was analyzed by microscopy with representative images shown. (B) IMR-32 cells were transfected with si*MYCN* or siNTC and the protein was analyzed by Western blot for N-myc and NSE at 8 and 12 h post-transfection. β -actin was used to check for equal protein loading.

reported that high *MYCN* expression selectively induces S-phase reentry while protecting against apoptosis in postmitotic sympathetic neurons [22]. A comparison of cell growth of *MYCN* amplified BE(2)-C cells (Fig. 2B) and *MYCN* non-amplified SK-N-SH and SH-SY5Y (data not shown) suggests that our si*MYCN* inhibited the proliferation of cells that overexpress N-myc. These results are comparable to those achieved with oligodeoxyribonucleotide [3].

In this study, treatment with si*MYCN* markedly induced apoptosis in *MYCN* amplified neuroblastoma cell lines. Furthermore, we confirmed the induction of apoptosis by determining the reduction of expression of Bcl-xL, an anti-apoptotic member of the Bcl-2 family. Bcl-xL is localized at the mitochondria and in the cytosol; the cytosolic fraction of Bcl-xL is targeted to the mitochondria during induction of apoptosis [23]. In addition, si*MYCN* treatment resulted in an augmentation of caspase-3 cleavage in *MYCN* amplified BE(2)-C cells. In contrast, caspase-3 cleavage was not detected in *MYCN* non-amplified SK-N-SH and SH-SY5Y cell lines after si*MYCN* treatment, further suggesting that *MYCN* inhibition leads to activation of the apoptotic pathway in neuroblastoma cells.

Neuroblastoma cells can differentiate when exposed to various stimuli [24]. Our results show that *MYCN* silencing is an effective inducer of differentiation as noted by the neurite-like extensions (Fig. 4A); further confirmed by expression of neuronal differentiation marker, NSE (8 and 12 h after treatment; Fig. 4B). These results are similar to studies by Galderisi et al. [25] following antisense-oligodeoxyribonucleotide-inhibition of N-myc expression in human neuroblastoma cells.

In summary, siRNA appears to be highly specific for amplified *MYCN*, resulting in promotion of apoptosis and differentiation. Compared with other antisense approaches, siRNAs offer a more active and effective

treatment option because of resistance to degradation by nucleases and increased specificity [18,26]. Understanding the mechanisms underlying the effects of *MYCN* silencing on differentiation and apoptosis should be further explored to improve treatment responses in patients with *MYCN* overexpressing neuroblastomas.

Acknowledgments

The authors thank Dr. Sunghoon Kim for thoughtful comments, Huiping Guo for quantitative RT-PCR assistance, and Karen Martin for manuscript preparation. This work was supported by Grants RO1 DK61470, RO1 DK48498, RO1 CA104748, and PO1 DK35608 from the National Institutes of Health.

References

- [1] H. Shimada, I.M. Ambros, L.P. Dehner, J. Hata, V.V. Joshi, B. Roald, Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee, *Cancer* 86 (1999) 349–363.
- [2] W.A. Weiss, K. Aldape, G. Mohapatra, B.G. Feuerstein, J.M. Bishop, Targeted expression of *MYCN* causes neuroblastoma in transgenic mice, *EMBO J.* 16 (1997) 2985–2995.
- [3] A. Negroni, S. Scarpa, A. Romeo, S. Ferrari, A. Modesti, G. Raschella, Decrease of proliferation rate and induction of differentiation by a *MYCN* antisense DNA oligomer in a human neuroblastoma cell line, *Cell Growth Differ.* 2 (1991) 511–518.
- [4] L. Whitesell, A. Rosolen, L.M. Neckers, Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines, *Mol. Cell Biol.* 11 (1991) 1360–1371.
- [5] R. Ponzelli, S. Katz, D. Barsyte-Lovejoy, L.Z. Penn, Cancer therapeutics: targeting the dark side of Myc, *Eur. J. Cancer* 41 (2005) 2485–2501.
- [6] S. Kim, J. Kang, W. Hu, B.M. Evers, D.H. Chung, Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas, *Int. J. Cancer* 103 (2003) 352–359.

- [7] J.D. Walton, D.R. Kattan, S.K. Thomas, B.A. Spengler, H.F. Guo, J.L. Biedler, N.K. Cheung, R.A. Ross, Characteristics of stem cells from human neuroblastoma cell lines and in tumors, *Neoplasia* 6 (2004) 838–845.
- [8] A.H. Wyllie, J.F. Kerr, A.R. Currie, Cell death: the significance of apoptosis, *Int. Rev. Cytol.* 68 (1980) 251–306.
- [9] R. Tonelli, S. Purgato, C. Camerin, R. Fronza, F. Bologna, S. Alboresi, M. Franzoni, R. Corradini, S. Sforza, A. Faccini, J.M. Shohet, R. Marchelli, A. Pession, Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis, *Mol. Cancer Ther.* 4 (2005) 779–786.
- [10] J. Yang, X. Liu, K. Bhalla, C.N. Kim, A.M. Ibrado, J. Cai, T.I. Peng, D.P. Jones, X. Wang, Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked, *Science* 275 (1997) 1129–1132.
- [11] P. Li, D. Nijhawan, I. Budihardjo, S.M. Srinivasula, M. Ahmad, E.S. Alnemri, X. Wang, Cytochrome *c* and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade, *Cell* 91 (1997) 479–489.
- [12] M. Schwab, K. Alitalo, K.H. Klempnauer, H.E. Varmus, J.M. Bishop, F. Gilbert, G. Brodeur, M. Goldstein, J. Trent, Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour, *Nature* 305 (1983) 245–248.
- [13] M. Schwab, MYCN in neuronal tumours, *Cancer Lett.* 204 (2004) 179–187.
- [14] M.A. Matzke, J.A. Birchler, RNAi-mediated pathways in the nucleus, *Nat. Rev. Genet.* 6 (2005) 24–35.
- [15] A.M. Krichevsky, K.S. Kosik, RNAi functions in cultured mammalian neurons, *Proc. Natl. Acad. Sci. USA* 99 (2002) 11926–11929.
- [16] K.V. Morris, S.W. Chan, S.E. Jacobsen, D.J. Looney, Small interfering RNA-induced transcriptional gene silencing in human cells, *Science* 305 (2004) 1289–1292.
- [17] Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, T. Muramatsu, A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics, *Cancer Res.* 64 (2004) 3365–3370.
- [18] J.R. Bertrand, M. Pottier, A. Vekris, P. Opolon, A. Maksimenko, C. Malvy, Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo, *Biochem. Biophys. Res. Commun.* 296 (2002) 1000–1004.
- [19] E. Song, S.K. Lee, J. Wang, N. Ince, N. Ouyang, J. Min, J. Chen, P. Shankar, J. Lieberman, RNA interference targeting Fas protects mice from fulminant hepatitis, *Nat. Med.* 9 (2003) 347–351.
- [20] P.G. Rychahou, L.N. Jackson, S.R. Silva, S. Rajaraman, B.M. Evers, Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma, *Ann. Surg.* 243 (2006) 833–842, discussion 843–834.
- [21] P. Provost, D. Dishart, J. Doucet, D. Frendewey, B. Samuelsson, O. Radmark, Ribonuclease activity and RNA binding of recombinant human Dicer, *EMBO J.* 21 (2002) 5864–5874.
- [22] K. Wartiovaara, F. Barnabe-Heider, F.D. Miller, D.R. Kaplan, N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons, *J. Neurosci.* 22 (2002) 815–824.
- [23] Y.T. Hsu, K.G. Wolter, R.J. Youle, Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis, *Proc. Natl. Acad. Sci. USA* 94 (1997) 3668–3672.
- [24] A. Edsjo, L. Holmquist, S. Pahlman, Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation, *Semin. Cancer Biol.* (2006).
- [25] U. Galderisi, G. Di Bernardo, M. Cipollaro, G. Peluso, A. Cascino, R. Cotrufo, M.A. Melone, Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product, *J. Cell Biochem.* 73 (1999) 97–105.
- [26] Y.H. Wang, S. Liu, G. Zhang, C.Q. Zhou, H.X. Zhu, X.B. Zhou, L.P. Quan, J.F. Bai, N.Z. Xu, Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo, *Breast Cancer Res.* 7 (2005) R220–R228.